Krystal Biotech (NASDAQ:KRYS) Shares Gap Up After Earnings Beat

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price gapped up prior to trading on Tuesday following a stronger than expected earnings report. The stock had previously closed at $276.45, but opened at $289.00. Krystal Biotech shares last traded at $285.45, with a volume of 212,409 shares changing hands.

The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 beat: Krystal reported $1.70 EPS (vs. $1.62 est.) and $107.1M in VYJUVEK Q4 revenue with 94% gross margin — evidence of profitable commercial traction and stronger net income. Read More.
• Positive Sentiment: Regulatory/designation wins: FDA granted RMAT for KB707 (advanced NSCLC) and Fast Track for KB111 (Hailey‑Hailey disease) — these expedite development and add optionality beyond VYJUVEK. Read More.
• Positive Sentiment: Commercial progress: Over ~660 U.S. reimbursements for VYJUVEK and growing uptake in Germany, France and Japan (90+ patients prescribed across those markets). The company reiterated expansion plans and a strong cash position (~$956M). Read More.
• Positive Sentiment: Analyst uplift: Chardan raised its price target to $323 and reiterated a Buy, adding upward analyst momentum and supporting valuation narratives. Read More.
• Neutral Sentiment: Conference materials and transcripts: The Q4 earnings call transcript, slide deck and investor webcast are available for detailed read‑throughs (helpful for assessing management commentary on growth drivers and expenses). Read More.
• Negative Sentiment: Mixed market reaction / share weakness: Multiple outlets reported KRYS shares slipped (>2%) despite the earnings beat — suggests profit‑taking and short‑term volatility after the print. Read More.
• Negative Sentiment: Reimbursement & launch timing risk in Europe: Pricing negotiations in Germany and France could push meaningful EU revenue later into 2H‑2026/2027, adding execution risk to international growth. Read More.
• Negative Sentiment: Expense / guidance transparency concerns: SG&A rose materially year‑over‑year and management provided non‑GAAP combined R&D+SG&A guidance that excludes stock‑based comp (company says it cannot reliably reconcile)—this can create uncertainty around forward GAAP profitability. Read More.
• Negative Sentiment: Insider selling: Data show material insider sales activity over recent months, which can weigh on investor sentiment even as institutions adjust positions. Read More.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KRYS. HC Wainwright reissued a “buy” rating and issued a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. The Goldman Sachs Group lifted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Bank of America raised their price target on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and a consensus target price of $307.22.

Insider Activity

In other news, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently made changes to their positions in KRYS. Hantz Financial Services Inc. boosted its position in shares of Krystal Biotech by 8,950.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after acquiring an additional 179 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. AdvisorNet Financial Inc bought a new stake in shares of Krystal Biotech in the 3rd quarter valued at approximately $30,000. Salomon & Ludwin LLC bought a new stake in shares of Krystal Biotech in the 3rd quarter valued at approximately $33,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of Krystal Biotech by 212.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

The company has a 50-day moving average of $264.84 and a 200 day moving average of $208.40. The firm has a market cap of $8.22 billion, a P/E ratio of 41.36 and a beta of 0.49.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.